<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id>
<journal-title-group>
<journal-title>Pediatric Rheumatology Online Journal</journal-title>
</journal-title-group>
<issn pub-type="epub">1546-0096</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27609179</article-id>
<article-id pub-id-type="pmc">5015262</article-id>
<article-id pub-id-type="publisher-id">111</article-id>
<article-id pub-id-type="doi">10.1186/s12969-016-0111-7</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Monogenic polyarteritis: the lesson of ADA2 deficiency</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Caorsi</surname>
<given-names>Roberta</given-names>
</name>
<address>
<email>robertacaorsi@hotmail.it</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Penco</surname>
<given-names>Federica</given-names>
</name>
<address>
<email>federica.penco@hotmail.it</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schena</surname>
<given-names>Francesca</given-names>
</name>
<address>
<email>fransche79@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gattorno</surname>
<given-names>Marco</given-names>
</name>
<address>
<email>marcogattorno@gaslini.org</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1">UO Pediatria II, Istituto G. Gaslini, Genoa, Italy </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>8</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>8</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>14</volume>
<issue>1</issue>
<elocation-id>51</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>9</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>The deficiency of Adenosine Deaminase 2 (DADA2) is a new autoinflammatory disease characterised by an early onset vasculopathy with livedoid skin rash associated with systemic manifestations, CNS involvement and mild immunodeficiency.</p>
<p>This condition is secondary to autosomal recessive mutations of <italic>CECR1</italic> (Cat Eye Syndrome Chromosome Region 1) gene, mapped to chromosome 22q11.1, that encodes for the enzymatic protein adenosine deaminase 2 (ADA2). By now 19 different mutations in <italic>CECR1</italic> gene have been detected.</p>
<p>The pathogenetic mechanism of DADA2 is still unclear. ADA2 in a secreted protein mainly expressed by cells of the myeloid lineage; its enzymatic activity is higher in conditions of hypoxia, inflammation and oncogenesis. Moreover ADA2 is able to induce macrophages proliferation and differentiation; it’s deficiency is in fact associated with a reduction of anti-inflammatory macrophages (M2). The deficiency of ADA2 is also associated with an up-regulation of neutrophils-expressed genes and an increased secretion of pro-inflammatory cytokines. The mild immunodeficiency detected in many DADA2 patients suggests a role of this protein in the adaptive immune response; an increased mortality of B cells and a reduction in the number of memory B cells, terminally differentiated B cells and plasmacells has been described in many patients. The lack of the protein is associated with endothelium damage; however the function of this protein in the endothelial homeostasis is still unknown.</p>
<p>From the clinical point of view, this disease is characterized by a wide spectrum of severity. Chronic or recurrent systemic inflammation with fever, elevation of acute phase reactants and skin manifestations (mainly represented by livedo reticularis) is the typical clinical picture. While in some patients the disease is mild and skin-limited, others present a severe, even lethal, disease with multi-organ involvement; the CNS involvement is rather common with ischemic or hemorrhagic strokes. In many patients not only the clinical picture but also the histopathologic features are undistinguishable from those of systemic polyarteritis nodosa (PAN). Of note, patients with an unusual phenotype, mainly dominated by clinical manifestations suggestive for an immune-disrective condition, have been described.</p>
<p>Due to its rarity, the response to treatment of DADA2 is still anecdotal. While steroids can control the disease’s manifestations at high dosage, none of the common immunosuppressive drugs turned out to be effective. Biologic drugs have been used only in few patients, without a clear effectiveness; anti-TNF drugs are those associated to a better clinical response. Hematopoietic stem cells transplantation was effective in patients with a severe phenotype.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p>The deficiency of Adenosine Deaminase 2 (DADA2) is a recently identified disease, gathered in the family of autoinflammatory diseases, mainly characterised by early-onset polyarteritis, hemorrhagic and ischemic strokes and hypogammaglobulinemia.</p>
<p>In February 2014 two independent studies, one held by the American National Institutes of Health in Bethesda [<xref ref-type="bibr" rid="CR1">1</xref>] and the other one by the Israeli Sharee Zedek Medical Center in Jerusalem [<xref ref-type="bibr" rid="CR2">2</xref>], identified this new clinical entity, often familial, characterised by early onset livedoid rash associated with systemic inflammation (fever and elevation of acute phase reactants). Some patients presented ischemic or haemorrhagic cerebral stroke, other vasculopathy-related manifestations (hypertension, gastrointestinal symptoms), hepatosplenomegaly, peripheral neuropathy and mild immunodeficiency.</p>
<p>In many cases both the clinical manifestations and the histological findings were consistent with the diagnosis of polyarteritis nodosa (PAN), with childhood-onset.</p>
<p>The analysis of the whole exome-sequencing (WES) in unrelated affected patients identified autosomal recessive deleterious mutations in <italic>CECR1</italic> gene, encoding for adenosine deaminase 2 (ADA2).</p>
<p>The marked reduction of both plasmatic levels and enzymatic activity of ADA2 detected in affected patients respect to healthy donors [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], confirmed the hypothesis that the causative mutation determines the loss-of-function of the protein. The non-affected simple-heterozygous parents displayed intermediate values of both plasmatic levels and enzymatic activity [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
</sec>
<sec id="Sec2">
<title><italic>CECR1</italic> gene</title>
<p>The <italic>CECR1</italic> (Cat Eye Syndrome Chromosome Region 1) gene, mapped to chromosome 22q11.1 and constituted by 10 exons [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], encodes for the enzyme adenosine deaminase 2 (ADA2), a protein composed by 4 domains: the signal sequence, the dimerization domain, the putative receptor-binding domain and the catalytic domain.</p>
<p>The mutations detected in <italic>CECR1</italic> gene so far are 19, with a different prevalence according to patient’s ethnicity (Table <xref ref-type="table" rid="Tab1">1</xref>, Fig. <xref ref-type="fig" rid="Fig1">1</xref>) [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR13">13</xref>]. The G47R mutation has been detected in homozygous state in all patients of Georgian Jewish and Turkish origin. Based on the results of the molecular analysis performed in 246 healthy donors of Georgian Jewish origin, the estimated frequency of this mutation in this population is 10 % [<xref ref-type="bibr" rid="CR2">2</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<italic>CECR1</italic> mutations so far detected</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Mutation</th><th>Exon</th><th>HGVS sequence name</th><th>Aminoacid substitution</th><th>N° of patients</th><th>Enzymatic domain</th></tr></thead><tbody><tr><td>M1T</td><td>2</td><td>c.2 T &gt; C</td><td>Met1Thr</td><td>1 in compound heterozygosis</td><td>Signal peptide</td></tr><tr><td>K13del</td><td>2</td><td>c.37_39del</td><td>37_39del</td><td>2 in compound heterozygosis</td><td>Signal peptide (?)</td></tr><tr><td>28-kb-deletion</td><td>2</td><td>deletion</td><td>deletion</td><td>1 in compound heterozygosis</td><td>5′UTR (5′untranslated region)</td></tr><tr><td rowspan="2">G47R</td><td rowspan="2">2</td><td rowspan="2">c.139G &gt; A</td><td rowspan="2">Gly47Arg</td><td>27 in homozygosis</td><td rowspan="2">Dimerization</td></tr><tr><td>1 in compound heterozygosis</td></tr><tr><td>G47A</td><td>2</td><td>c.140G &gt; C</td><td>Gly47Ala</td><td>2 in compound heterozygosis</td><td>Dimerization</td></tr><tr><td>G47V</td><td>2</td><td>c.140G &gt; T</td><td>Gly47Val</td><td>1 in compound heterozygosis</td><td>Dimerization</td></tr><tr><td>I93T</td><td>2</td><td>c.278 T &gt; C</td><td>Ile93Thr</td><td>1 in compound heterozygosis</td><td>Dimerization</td></tr><tr><td>A109D</td><td>3</td><td>c.326C &gt; A</td><td>Ala109Asp</td><td>1 in compound heterozygosis</td><td>Catalytic</td></tr><tr><td>H112Q</td><td>3</td><td>c.336C &gt; G</td><td>His112Gln</td><td>1 in compound heterozygosis</td><td>Catalytic</td></tr><tr><td>T119A</td><td>3</td><td>c.355A &gt; G</td><td>Thr119Ala</td><td>4 in compound heterozygosis</td><td>Catalytic</td></tr><tr><td>G142S</td><td>3</td><td>c.424G &gt; A</td><td>Gly142Ser</td><td>4 in compound heterozygosis</td><td>Catalytic</td></tr><tr><td rowspan="2">R169Q</td><td rowspan="2">3</td><td rowspan="2">c.506G &gt; A</td><td rowspan="2">Arg169Gln</td><td>15 in homozygosis</td><td rowspan="2">PBR (putative receptor-binding)</td></tr><tr><td>9 in compound heterozygosis</td></tr><tr><td>P193L</td><td>4</td><td>c.578C &gt; T</td><td>Pro193Leu</td><td>1 in compound heterozygosis</td><td>Catalytic (?)</td></tr><tr><td>M243R</td><td>4</td><td>NA</td><td>Met243Arg</td><td>2 in compound heterozygosis</td><td>Catalytic</td></tr><tr><td>P251L</td><td>4</td><td>c.752C &gt; T</td><td>Pro251Leu</td><td>4 in compound heterozygosis</td><td>Catalytic</td></tr><tr><td>W264S</td><td>5</td><td>c.791G &gt; C</td><td>Trp264Ser</td><td>1 in compound heterozygosis</td><td>Catalytic</td></tr><tr><td>R306*</td><td>6</td><td>c.916C &gt; T</td><td>p.Arg306*</td><td>1 in compound heterozygosis</td><td>Catalytic (?)</td></tr><tr><td>N328K</td><td>7</td><td>c.1159C &gt; A</td><td>Cys1159Arg</td><td>2 in compound heterozygosis</td><td>Catalytic</td></tr><tr><td>Y453C</td><td>9</td><td>c.1358A &gt; G</td><td>Tyr453Cys</td><td>3 in compound heterozygosis</td><td>Catalytic</td></tr></tbody></table><table-wrap-foot><p>Legend: HGVS: Human Genome Variation Society</p><p>
<italic>NA</italic> not available</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Cat Eye Syndrome Chromosome Region 1 (<italic>CECR1</italic>) gene and Adenosine Deaminase 2 (ADA2) protein with the mutations by now detected</p></caption><graphic id="MO1" xlink:href="12969_2016_111_Fig1_HTML"></graphic></fig></p>
<p>Conversely, the R169Q is the mutation more frequently detected in the European Caucasian population [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p>
<p>The mutations so far detected affect the Signal peptide (<italic>n</italic> = 2), the 5’ untranslated region (<italic>n</italic> = 1), the dimerization domain (<italic>n</italic> = 4), the putative receptor binding (<italic>n</italic> = 1) and the catalytic domain (<italic>n</italic> = 11) (Table <xref ref-type="table" rid="Tab1">1</xref>, Fig. <xref ref-type="fig" rid="Fig1">1</xref>) [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover two patients with a homozygous deletion on 22.11.1 chromosome (encompassing <italic>CECR1</italic> gene) have been recently described [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
<sec id="Sec3">
<title>ADA2 protein and pathogenetic mechanisms</title>
<p>The enzyme Adenosine Deaminase (ADA) plays a key role in the purine metabolism converting adenosine to inosine and 2′-deoxyadenosine to 2′-deoxyinosine [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
<p>The two major ADA isoforms are ADA1, whose deficiency is cause of a severe combined immunodeficiency (SCID) [<xref ref-type="bibr" rid="CR16">16</xref>], and ADA2.</p>
<p>Even if the two proteins have partial structural homology, the two isoenzymes differ in many aspects: the affinity of ADA2 for molecules of adenosine and deoxy-adenosine is about 100 times lower than that of ADA1; consequently, at physiological concentrations of substrate, the deaminase activity of ADA2 is almost absent [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
<p>While ADA1 is monomeric and acts primarily intracellularly, ADA2 is dimeric and secreted in the extracellular environment where it exerts its main functions. For this reason ADA2 is clearly detectable in the plasma. Finally, while ADA1 is ubiquitally expressed in all cell types, ADA2 is mostly expressed by monocytes and other cells of the myeloid lineage [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
<p>ADA2 is more stable at high temperatures and the optimum pH for its activity is generally acid (about 6.5), which suggests a specialized role of this enzyme in conditions of hypoxia, inflammation and oncogenesis; in these conditions its deaminase activity is higher [<xref ref-type="bibr" rid="CR17">17</xref>] (Fig. <xref ref-type="fig" rid="Fig2">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Production and physiological role of Adenosine Deaminase 2 (ADA2). ADA2 is produced and secreted by cells of myeloid lineage; it exerts its enzymatic activity in the extracellular space, especially in the presence of a low pH or high temperature. On monocytes (<bold>a</bold>) ADA2 acts as growth-factor with an autocrine activity: it induces monocytes’ proliferation and promote the differentiation of M2 anti-inflammatory macrophages. On neutrophils (<bold>b</bold>) ADA2 induces the gene of expression of some pro-inflammatory proteins, such as myeloperoxidase (MPO) and neutrophils’ activations, leading to the secretion of pro-inflammatory cytokines. There are indirect evidences of a possible role of ADA2 as growth-factor for endothelial cells (<bold>c</bold>)</p></caption><graphic id="MO2" xlink:href="12969_2016_111_Fig2_HTML"></graphic></fig></p>
<p>The capacity of binding receptors involved in the signal transduction of different pathways (such as proteoglycans), confers to ADA2 a growth-factor like action; for this reason ADA2 is considered an Adenosine Deaminase-related Growth-Factor (ADGF) [<xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR19">19</xref>] (Fig. <xref ref-type="fig" rid="Fig2">2</xref>).</p>
<p>ADA2 displays also an autocrine activity: the protein, released by activated monocytes, is able to induce monocyte proliferation and macrophage differentiation [<xref ref-type="bibr" rid="CR20">20</xref>]; <italic>CECR1</italic> silencing in myeloid cells is in fact associated to a reduced differentiation of monocytes to macrophages [<xref ref-type="bibr" rid="CR1">1</xref>]. This activity has been demonstrated to be mediated by the direct binding of cellular receptors, and therefore to be independent from the enzymatic activity [<xref ref-type="bibr" rid="CR20">20</xref>] (Fig. <xref ref-type="fig" rid="Fig2">2</xref>).</p>
<p>ADA2 seems to be also involved in the balance between pro-inflammatory (M1) and anti-inflammatory (M2) monocytes; its absence has been in fact associated with a defect in differentiation of M2 macrophages, which leads to a prevalence of pro-inflammatory M1 cells [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
<p>Microarray analysis in two DADA2 patients showed a marked up-regulation of neutrophils-expressed genes. Intracellular staining revealed an increased expression of myeloperoxidase (MPO) in peripheral blood mononuclear cells compared to controls [<xref ref-type="bibr" rid="CR8">8</xref>] (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). According with these findings, the assessment of cytokine levels performed in the serum of few described patients revealed an increase of pro-inflammatory cytokines: in the two patients carrying a homozygous deletion of 22q11.1 chromosome increased levels of both IL-1β and TNFα were detected [<xref ref-type="bibr" rid="CR14">14</xref>], while in another case the detection of IL-6 revealed increased levels [<xref ref-type="bibr" rid="CR7">7</xref>]. These data are in contrast with the results obtained in the NIH study, in which the cytokine assay performed in the supernatants of the whole blood cell cultured with different stimuli did not reveal any significant difference between patients and healthy donors [<xref ref-type="bibr" rid="CR1">1</xref>]. Further studies on larger series of patients are therefore needed in order to investigate the cytokines’ pattern in DADA2; in particular the cytokines’ production should be assessed in stimulated PBMCs and should take into consideration the disease activity.</p>
<p>It has been also postulated that the deregulation of purinergic stimulation, due to the decrease of the enzymatic activity of ADA2, may play a pro-inflammatory role. Adenosine is in fact an important signaling molecule that can modulate the inflammatory response; its concentration in tissues is normally low and increases in condition of cellular stress, ischemia or inflammation [<xref ref-type="bibr" rid="CR21">21</xref>]. The accumulation of adenosine can influence the inflammatory response by binding several receptors that lead to inflammation, tissue damage and fibrosis [<xref ref-type="bibr" rid="CR21">21</xref>]. However, the plasmatic levels of adenosine and deoxiadenosine in few DADA2 patients has been detected within the normal range [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p>
<p>Since hypogammaglobulinemia has been described in some patients, adaptive immunity has been investigated in ADA2 patients. A reduction in the number of memory B cells, terminally differentiated B cells and plasmacells has been described [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]; moreover co-culture experiments have enlightened an increased mortality of B cells [<xref ref-type="bibr" rid="CR1">1</xref>]. Not univocal results have been detected concerning the T cells function. In fact, while in the NIH study ADA2 mutations seem not to affect T lymphocyte number and activation [<xref ref-type="bibr" rid="CR1">1</xref>], in a more recent study an increase of regulatory T cells and a decrease of CD8+ and CD4 + memory T cells have been detected in one patient with DADA2 [<xref ref-type="bibr" rid="CR7">7</xref>]. In addition a reduced number of Th1, Th2 and follicular T helper (Tfh) cells has been observed in the same patient.</p>
<p>The reason why endothelium represents the main target of inflammation in DADA2 is still largely unknown. ADA2 acts as a growth-factor for endothelial cells. In fact, even if it has been demonstrated that endothelial cells do not express <italic>CECR1</italic> gene, the deficiency of ADA2 is associated to a damage of vascular endothelium and to an over expression of activation markers [<xref ref-type="bibr" rid="CR1">1</xref>]. The knockdown animal model for <italic>CECR1</italic> gene (zebrafish) displays cerebral haemorrhages without morphologic alteration in the vascular structure; these episodes recovered following the transfection of non-mutant human <italic>CECR1</italic> messenger RNA [<xref ref-type="bibr" rid="CR1">1</xref>]. In the same way, monocytes of patients with DADA2 led to destruction of co-cultured human microvascular endothelial cells [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
<p>Due to the rarity of the disease, all available data on the pathogenic consequences of ADA2 defect in humans come from few patients; further studies are therefore needed in order to better enlighten the activity of ADA2 in the innate and adaptive immune response and its role in the endothelium homeostasis.</p>
</sec>
<sec id="Sec4">
<title>Clinical manifestations</title>
<p>DADA2 can be defined as an inflammatory vasculopathy with a wide range of clinical manifestations, possibly associated with an immunodeficiency of variable severity.</p>
<p>The disease is mainly characterized by chronic or recurrent systemic inflammation with fever and elevation of acute phase reactants, usually associated with different possible skin manifestations, ranging from the most frequent livedo reticularis (Fig. <xref ref-type="fig" rid="Fig3">3</xref>) to maculopapular rash, nodules, purpura, erythema nodosum, Raynaud’s phenomenon, ulcerative lesions, digital necrosis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].<fig id="Fig3"><label>Fig. 3</label><caption><p>Livedo reticularis in a patient with DADA2</p></caption><graphic id="MO3" xlink:href="12969_2016_111_Fig3_HTML"></graphic></fig></p>
<p>The clinical picture is wide, ranging form a mild disease with a late onset skin-limited involvement to a very severe systemic phenotype (even fatal) with an early onset and a multi-organ involvement (Tables <xref ref-type="table" rid="Tab2">2</xref> and <xref ref-type="table" rid="Tab3">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinical manifestation of DADA2 patients so far described</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Report</th><th>
<italic>CECR1</italic>
<break></break>Mutation</th><th>Ethnicity</th><th>Age at onset</th><th>Fever</th><th>Skin</th><th>CNS/PNS</th><th>Gastro-intestinal</th><th>Immune/Hematologic system</th><th>ANA</th><th>ANCA</th><th>Hypertension</th><th>Other</th></tr></thead><tbody><tr><td rowspan="24">Navon et al.</td><td>1</td><td>G47R/G47R</td><td>Georgian</td><td>2 m</td><td>Yes</td><td>Ulcerations at extremities</td><td>No</td><td>Intestinal necrosis</td><td>No</td><td>neg</td><td>neg</td><td>Yes</td><td>Coronary aneurysms</td></tr><tr><td>2</td><td>G47R/G47R</td><td>Georgian</td><td>5 y</td><td>No</td><td>Livedo reticularis, nodules, purpuric rash</td><td>No</td><td>Intestinal vasculitis</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>3</td><td>G47R/G47R</td><td>Georgian</td><td>7 m</td><td>Yes</td><td>Livedo reticularis, papulo-nodular rash, Raynaud’s phenomenon</td><td>Ischemic stroke, peripheral paresis of cranial nerves</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>Yes</td><td>Arthritis</td></tr><tr><td>4</td><td>G47R/G47R</td><td>Georgian</td><td>3,5 y</td><td>Yes</td><td>Livedo reticularis, nodules, purpuric rash, erythema nodosum</td><td>Cranial nerve paralysis</td><td>No</td><td>No</td><td>pos</td><td>ND</td><td>No</td><td>No</td></tr><tr><td>5</td><td>G47R/G47R</td><td>Georgian</td><td>2,5 y</td><td>No</td><td>Maculopapular rash, nodules</td><td>Neurosensorial hearing loss</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>Arthritis</td></tr><tr><td>6</td><td>G47R/G47R</td><td>Georgian</td><td>2 m (died at 9 m)</td><td>Yes</td><td>Digital necrosis</td><td>Ventricular haemorrhage</td><td>Aneurism of celiac artery</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>7</td><td>G47R/G47R</td><td>Georgian</td><td>2 m</td><td>Yes</td><td>Livedo reticularis, Raynaud’s phenomenon</td><td>No</td><td>Abdominal pain</td><td>No</td><td>neg</td><td>ND</td><td>No</td><td>No</td></tr><tr><td>8</td><td>G47R/G47R</td><td>Georgian</td><td>6,5 y</td><td>Yes</td><td>Livedo reticularis, nodules, Raynaud’s phenomenon</td><td>No</td><td>Abdominal pain</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>9</td><td>G47R/G47R</td><td>Georgian</td><td>9 y</td><td>No</td><td>Livedo reticularis</td><td>No</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>10</td><td>G47R/G47R</td><td>Georgian</td><td>10 y</td><td>No</td><td>Livedo reticularis, nodules, Raynaud’s phenomenon, leg ulcers</td><td>No</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>11</td><td>G47R/G47R</td><td>Georgian</td><td>59 y</td><td>No</td><td>Leg ulcers</td><td>No</td><td>No</td><td>No</td><td>neg</td><td>ND</td><td>No</td><td>No</td></tr><tr><td>12</td><td>G47R/G47R</td><td>Georgian</td><td>childhood (died at 30 y)</td><td>No</td><td>Livedo reticularis, nodules, Raynaud’s phenomenon, leg ulcers with amputation</td><td>No</td><td>No</td><td>No</td><td>ND</td><td>ND</td><td>No</td><td>No</td></tr><tr><td>13</td><td>G47R/G47R</td><td>Georgian</td><td>1 y</td><td>No</td><td>Livedo reticularis, nodules, Raynaud’s phenomenon</td><td>Sensitive polyneuropathy</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>14</td><td>G47R/G47R</td><td>Georgian</td><td>4 y</td><td>Yes</td><td>Livedo reticularis, purpuric rash, skin nodules.</td><td>No</td><td>No</td><td>No</td><td>pos</td><td>ND</td><td>No</td><td>No</td></tr><tr><td>15</td><td>G47R/G47R</td><td>Georgian</td><td>1 y</td><td>Yes</td><td>Livedo reticularis</td><td>No</td><td>Abdominal pain</td><td>No</td><td>neg</td><td>neg</td><td>Yes</td><td>Mesenteric and renal infarcts</td></tr><tr><td>16</td><td>G47R/G47R</td><td>Georgian</td><td>18 y</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>17</td><td>G47R/G47R</td><td>Georgian</td><td>28 y</td><td>Yes</td><td>Raynaud’s phenomenon, purpuric rash, leg ulcers with digital amputation</td><td>Polyneuropathy</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>Yes</td><td>Panniculitis</td></tr><tr><td>18</td><td>G47R/G47R</td><td>Georgian</td><td>2 y</td><td>No</td><td>Skin nodules</td><td>Polyneuropathy</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>19</td><td>G47R/G47R</td><td>Georgian</td><td>16 y</td><td>No</td><td>Raynaud’s phenomenon, ulceration of extremities</td><td>No</td><td>No</td><td>No</td><td>pos</td><td>neg</td><td>Yes</td><td>No</td></tr><tr><td>20</td><td>R169Q/P251L</td><td>European Caucasian</td><td>1 y</td><td>Yes</td><td>Livedo reticularis</td><td>Ischemic stroke, cranial nerves (II,VI,VII) paralysis</td><td>No</td><td>No</td><td>neg</td><td>ND</td><td>Yes</td><td>No</td></tr><tr><td>21</td><td>R169Q/P251L</td><td>European Caucasian</td><td>12 y</td><td>No</td><td>No</td><td>Ischemic stroke, VII cranial nerve paralysis</td><td>No</td><td>No</td><td>pos</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>22</td><td>R169Q/P251L</td><td>European Caucasian</td><td>1 y</td><td>No</td><td>Livedo reticularis, skin rash at extremities</td><td>Ischemic stroke<break></break>VI cranial nerve paralysis, neurosensorial hearing loss</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>23</td><td>R169Q/P251L</td><td>European Caucasian</td><td>3 m</td><td>No</td><td>Livedo reticularis, vasculitic exanthema of lower extremities</td><td>VII cranial nerve paralysis</td><td>No</td><td>No</td><td>ND</td><td>ND</td><td>No</td><td>Epididymitis</td></tr><tr><td>24</td><td>G47V/W264S</td><td>Turkish</td><td>10 y</td><td>Yes</td><td>Livedo reticularis</td><td>No</td><td>No</td><td>No</td><td>neg</td><td>ND</td><td>Yes</td><td>Myalgia, abdominal and renal aneurysm</td></tr><tr><td rowspan="9">Zhou et al.</td><td>1</td><td>A109D/Y453C</td><td>European Caucasian</td><td>2 y</td><td>Yes</td><td>Livedo reticularis</td><td>Ischemic stroke</td><td>Splenomegaly</td><td>No</td><td>pos</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>2</td><td>G47A/Y453C</td><td>European Caucasian</td><td>1 y</td><td>Yes</td><td>Livedo reticularis, erythematous and urticarial rash</td><td>Ischemic and haemorrhagic strokes</td><td>Hepatomegaly, splenomegaly. Portal hypertension.</td><td>Pancytopenia, hypoIg</td><td>pos</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>3</td><td>R169Q/deletion</td><td>European Caucasian</td><td>1,5 y</td><td>Yes</td><td>Livedo reticularis, urticarial rash</td><td>Ischemic and haemorrhagic strokes</td><td>Hepatomegaly, splenomegaly, chronic gastritis</td><td>Leucopoenia, hypoIg</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>4</td><td>G47A/H112Q</td><td>European Caucasian</td><td>5 m</td><td>Yes</td><td>Livedo reticularis, urticarial rash</td><td>Ischemic and haemorrhagic strokes</td><td>Hepatomegaly, splenomegaly, portal hypertension.</td><td>Pancytopenia, HypoIg</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>5</td><td>R169Q/Y453C</td><td>European Caucasian</td><td>1,5 y</td><td>Yes</td><td>Livedo reticularis</td><td>Ischemic stroke</td><td>Hepatomegaly, splenomegaly.</td><td>Leucopoenia, hypoIg</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>6</td><td>M1T/I93T</td><td>European Caucasian</td><td>1,5 y (died 16 y)</td><td>Yes</td><td>Non-Langerhans cell<break></break>histiocytosis</td><td>Ischemic stroke</td><td>Hepatomegaly, splenomegaly. portal hypertension.</td><td>No</td><td>neg</td><td>neg</td><td>Yes</td><td>Evans syndrome</td></tr><tr><td>7</td><td>G47R/G47R</td><td>Turkish</td><td>3,5 y</td><td>Yes</td><td>Livedo reticularis, erythema nodosum</td><td>Ischemic stroke<break></break>III cranial nerve paralysis</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>8</td><td>G47R/G47R</td><td>Tukish</td><td>4 y</td><td>Yes</td><td>Livedo reticularis, erythema nodosum</td><td>Ischemic stroke</td><td>Bowel perforation</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>Macrophage activation syndrome</td></tr><tr><td>9</td><td>G47R/G47R</td><td>Turkish</td><td>9 y (died 22 y)</td><td>Yes</td><td>Livedo reticularis, ulceration of extremities</td><td>No</td><td>Hepatomegaly, splenomegaly</td><td>Leucopoenia</td><td>pos</td><td>neg</td><td>No</td><td>Renal amyloidosis, necrotising pneumonia</td></tr><tr><td rowspan="2">van Montfrans et al.</td><td>1</td><td>R169Q/R169Q</td><td>NA</td><td>6 m</td><td>No</td><td>Livedo reticularis</td><td>No</td><td>Hepatomegaly, splenomegaly</td><td>Granulocytopenia, red-cell aplasia</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>2</td><td>R169Q/R169Q</td><td>NA</td><td>6 y</td><td>Yes</td><td>Livedo reticularis</td><td>Stroke</td><td>Hepatomegaly, splenomegaly</td><td>HypoIg, lymphopenia</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td rowspan="4">Bras et al.</td><td>1</td><td>T119A/G142S</td><td>European Caucasian</td><td>&gt;10 y</td><td>Yes</td><td>Livedo reticularis, ulcerations of extremities</td><td>Stroke</td><td>No</td><td>No</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>2</td><td>T119A/G142S</td><td>European Caucasian</td><td>&gt;10 y</td><td>Yes</td><td>Livedo reticularis, ulcerations of extremities</td><td>Stroke</td><td>No</td><td>No</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>3</td><td>T119A/G142S</td><td>European Caucasian</td><td>&gt;10 y</td><td>Yes</td><td>Livedo reticularis, ulcerations of extremities</td><td>Stroke</td><td>No</td><td>No</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>4</td><td>T119A/G142S</td><td>European Caucasian</td><td>&gt;10 y</td><td>Yes</td><td>Livedo reticularis, ulcerations of extremities</td><td>Stroke</td><td>No</td><td>No</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>Van Eyck et al.</td><td>1</td><td>G47R/G47R</td><td>NA</td><td>5 y</td><td>Yes</td><td>No</td><td>No</td><td>Splenomegaly</td><td>Lymphadenopathy, anaemia, thrombocytosis</td><td>NA</td><td>NA</td><td>No</td><td></td></tr><tr><td>Garg et al.</td><td>1</td><td>G47R/R306*</td><td>Turkish</td><td>1,5 y (died 5 y)</td><td>Yes</td><td>Skin rash</td><td>Hemorrhagic and ischemic stroke.<break></break>intraparenchymal haemorrhage</td><td>No</td><td>No</td><td>neg</td><td>neg</td><td>No</td><td>Acute respiratory distress syndrome</td></tr><tr><td rowspan="2">Van Eyck et al.</td><td>1</td><td>R169Q/R169Q</td><td>African/ Caucasian</td><td>6 m</td><td>No</td><td>No</td><td>Haemorrhagic stroke</td><td>Splenomegaly</td><td>Pancytopenia, hypoIg, lymphadenopathy, recurrent viral infections</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>2</td><td>R169Q/R169Q</td><td>African/ Caucasian</td><td>5 m</td><td>No</td><td>No</td><td>TIA</td><td>Bowel perforation (ulcerative bowel disease, no signs of vasculitis)</td><td>Leucopoenia, hypoIg, lymphadenopathy, recurrent viral infections</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td rowspan="2">Belot et al.</td><td>1</td><td>R169Q/P193L</td><td>European Caucasian</td><td>First year</td><td>Yes</td><td>Livedo reticularis, ulceration of extremities</td><td>TIA, ischemic stroke, sensitive polyneuropathy, intracerebral haemorrhage.</td><td>Bowel stenosis</td><td>HypoIg</td><td>neg</td><td>neg</td><td>No</td><td>Oral aphtae</td></tr><tr><td>2</td><td>G47R/G47R</td><td>Asian</td><td>1 m</td><td>Yes</td><td>Erythema nodosum, vasculitic rash</td><td>Intracerebral haemorrhage, Ischemic stroke, Optic neuritis</td><td>No</td><td>No</td><td>NA</td><td>NA</td><td>Yes</td><td>Dactylitis, aneurysm of abdominal vessels</td></tr><tr><td rowspan="2">Westendorp et al.</td><td>1</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>3 y</td><td>No</td><td>Livedo reticularis, nodules</td><td>Ischemic stroke, peripheral neuropathy<break></break>neurosensorial hearing loss</td><td>No</td><td>No</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>2</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>2 y</td><td>No</td><td>Livedo reticularis</td><td>Ischemic stroke</td><td>No</td><td>No</td><td>NA</td><td>NA</td><td>No</td><td>Autism</td></tr><tr><td rowspan="2">Gonzales Santiago et al.</td><td>1</td><td>K13del/N328K</td><td>European Caucasian</td><td>2 y</td><td>Yes</td><td>Livedo racemosa</td><td>No</td><td>No</td><td>HypoIg</td><td>NA</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>2</td><td>K13del/N328K</td><td>European Caucasian</td><td>5 y</td><td>No</td><td>Nodules, erytema of lower extremities</td><td>No</td><td>No</td><td>HypoIg, recurrent infections</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td rowspan="3">Batu et al.</td><td>1</td><td>G47R/G47R</td><td>Turkish</td><td>6,5 y</td><td>Yes</td><td>Livedo reticularis,</td><td>No</td><td>Abdominal pain</td><td>No</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td>2</td><td>G47R/G47R</td><td>Turkish</td><td>4 y</td><td>Yes</td><td>Livedo reticularis, erythema nodosum, necrotic ulcers</td><td>Stroke</td><td>Abdominal pain, hypertransaminasemia</td><td>No</td><td>pos</td><td>NA</td><td>Yes</td><td>Glomerulosclerosis</td></tr><tr><td>3</td><td>G47R/G47R</td><td>Turkish</td><td>10 y</td><td>Yes</td><td>Livedo reticularis</td><td>No</td><td>Abdominal pain</td><td>No</td><td>NA</td><td>NA</td><td>No</td><td>No</td></tr><tr><td rowspan="9">Van Montfrans et al.</td><td>1</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>1 y</td><td>Yes</td><td>Livedo reticularis, erythema nodosum, eczema, Raynaud phenomenon</td><td>Ischemic stroke, III cranial nerve paralysis</td><td>Abdominal pain, hepatomegaly</td><td>Adenopathy, hypoIg, pancytopenia</td><td>neg</td><td>neg</td><td>No</td><td>Oral aphtae, arthralgia<break></break>GH deficiency</td></tr><tr><td>2</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>Birth</td><td>No</td><td>Livedo reticularis, eczema</td><td>No</td><td>Abdominal pain, hepatomegaly, splenomegaly</td><td>HypoIg, anaemia</td><td>ND</td><td>ND</td><td>No</td><td>Jugular vein thrombosis, GH deficiency</td></tr><tr><td>3</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>6 y</td><td>No</td><td>Livedo reticularis, ulceration of extremities and trunk</td><td>No</td><td>Hepatomegaly, splenomegaly</td><td>Adenopathy, anaemia</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>4</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>3 y</td><td>No</td><td>Livedo racemosa, erythema nodosum, Raynaud phenomenon</td><td>Ischemic stroke, VI cranial nerve paralysis</td><td>Hepatomegaly, splenomegaly</td><td>HypoIg, recurrent infections, anaemia</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>5</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>1y</td><td>No</td><td>Eczema</td><td>Ischemic stroke, IV cranial nerve paralysis</td><td>Splenomegaly</td><td>HypoIg, anaemia, leucopoenia</td><td>neg</td><td>ND</td><td>No</td><td>Autism</td></tr><tr><td>6</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>9 m</td><td>Yes</td><td>Eczema</td><td>Ischemic stroke, IV cranial nerve paralysis</td><td>Abdominal pain, hepatomegaly, splenomegaly</td><td>HypoIg, pancytopenia</td><td>pos</td><td>pos</td><td>Yes</td><td>Oral aphtae, arthralgia</td></tr><tr><td>7</td><td>R169Q/R169Q</td><td>European Caucasian</td><td>8 y</td><td>Yes</td><td>Rash</td><td>Ischemic stroke, III cranial nerve paralysis</td><td>Abdominal pain, acute liver failure</td><td>HypoIg, recurrent infections, anaemia,lymphopenia</td><td>neg</td><td>neg</td><td>No</td><td>Oral aphtae, arthralgia</td></tr><tr><td>8</td><td>R169Q/R169Q</td><td>African/Caucasian</td><td>6 m</td><td>No</td><td>Eczema</td><td>Intracranial haemorrhage</td><td>Hepatomegaly, splenomegaly</td><td>HypoIg, adenopath, thrombocytopenia, leucopoenia</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td>9</td><td>R169Q/R169Q</td><td>African/Caucasian</td><td>5 m</td><td>No</td><td>No</td><td>No</td><td>Bowel ulcerations, colitis, hepatomegaly, splenomegaly</td><td>HypoIg, recurrent infections, adenopathy</td><td>neg</td><td>neg</td><td>No</td><td>No</td></tr><tr><td rowspan="2">Fellmann et al.</td><td>1</td><td>Homozygous 22q11.1 deletion (<italic>IL17RA</italic> and <italic>CECR1</italic>)</td><td>Asian</td><td>Birth (Died 16 y)</td><td>No</td><td>Ichthyosiform rash, oro-vaginal ulcerations</td><td>No</td><td>No</td><td>Recurrent infection (C. Albicans, S. aureus), neutropenia</td><td>neg</td><td>neg</td><td>No</td><td>Chronic systemic inflammation, failure to thrive</td></tr><tr><td>2</td><td>Homozygous 22q11.1 deletion (<italic>IL17RA</italic> and <italic>CECR1</italic>)</td><td>Asian</td><td>2 y</td><td>No</td><td>Ichthyosiform rash</td><td>No</td><td>Splenomegaly</td><td>Oro-vaginal candidiasis, Staphylococcal skin infections</td><td>neg</td><td>neg</td><td>No</td><td>Retinal vasculitis</td></tr><tr><td rowspan="2">Schepp et al.</td><td>1</td><td>R169Q/<break></break>M243R</td><td>NA</td><td>18 y</td><td>No</td><td>No</td><td>No</td><td>Splenomegaly</td><td>HypoIg, recurrent respiratory infections</td><td>NA</td><td>NA</td><td>No</td><td>Arthralgia</td></tr><tr><td>2</td><td>R169Q/M243R</td><td>NA</td><td>2 m (Died 17 y)</td><td>Yes</td><td>Erythema nodosum</td><td>Intracranial haemorrhage</td><td>Splenomegaly</td><td>HypoIg, lymphopenia, recurrent urinary tract and respiratory infections</td><td>neg</td><td>NA</td><td>No</td><td>Arthritis<break></break>Failure to thrive.</td></tr></tbody></table><table-wrap-foot><p>Legend: <italic>CNS</italic> central nervous system</p><p>
<italic>PNS</italic> peripheral nervous system</p><p>
<italic>TIA</italic> transitory ischemic attack</p><p>
<italic>GH</italic> growth hormone</p><p>
<italic>HypoIg</italic> Hypogammaglobulinemia</p><p>
<italic>ND</italic> not done</p><p>
<italic>NA</italic> not available</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>genotype/phenotype correlation in DADA2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Mutation</th><th>Exon</th><th>N° of patients</th><th>Associated symptoms (% of patients)</th></tr></thead><tbody><tr><td>M1T</td><td>2</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: Non-Langerhans cell histiocytosis<break></break>CNS/PNS: ischemic stroke<break></break>Visceral: involvement: hepatomegaly, splenomegaly. portal hypertension, hypertension (100 %)</td></tr><tr><td>K13del</td><td>2</td><td>2 in heterozygosis</td><td>Fever (50 %)<break></break>Skin: Livedo racemosa (50 %), skin nodules (50 %)<break></break>Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (50 %)</td></tr><tr><td>28-kb-deletion</td><td>2</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: Livedo reticularis, urticarial rash<break></break>CNS/PNS: ischemic and haemorrhagic strokes<break></break>Visceral involvement: hepatomegaly, splenomegaly. chronic gastritis<break></break>Immune/hematologic system: leukopenia, hypogammaglobulinemia (100 %)</td></tr><tr><td rowspan="2">G47R</td><td rowspan="2">2</td><td>27 in homozygosis</td><td rowspan="2">Fever (64 %)<break></break>Skin: Livedo reticularis (60 %), skin nodules (35 %), ulcerations at extremities/digital necrosis (32 %), Raynaud’s phenomenon (28 %), purpuric/vasculitic rash (18 %), erythema nodosum (18 %), panniculitis (3 %)<break></break>CNS/PNS: ischemic stroke (21 %), hemorrhagic stroke (7 %), intracranial haemorrhage (11 %), cranial nerve paralysis (14 %), polineuropathy (11 %), neurosensorial hearing loss (3 %).<break></break>Visceral involvement: abdominal pain (21 %), intestinal vasculitis (14 %), hepatomegaly (3 %), splenomegaly (7 %), hypertransaminasemia (3 %), hypertension (25 %).<break></break>Immune/hematologic system: Leucopoenia (3 %), anaemia (3 %), lymphadenopathy (3 %).</td></tr><tr><td>1 in heterozygosis</td></tr><tr><td>G47A</td><td>2</td><td>2 in heterozygosis</td><td>Fever (100 %)<break></break>Skin: Livedo reticularis (100 %), urticarial rash (100 %)<break></break>CNS/PNS: ischemic and haemorrhagic strokes (100 %)<break></break>Visceral involvement: hepatomegaly (100 %), splenomegaly (100 %), portal hypertension (100 %)<break></break>Immune/hematologic system: Pancytopenia (100 %), hypogammaglobulinemia (100 %).</td></tr><tr><td>G47V</td><td>2</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: Livedo reticularis<break></break>Visceral involvement: hypertension, abdominal and renal aneurysm (100 %).</td></tr><tr><td>I93T</td><td>2</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: Non-Langerhans cell histiocytosis<break></break>CNS/PNS: ischemic stroke<break></break>Visceral: involvement: hepatomegaly, splenomegaly. portal hypertension, hypertension (100 %)</td></tr><tr><td>A109D</td><td>3</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: Livedo reticularis<break></break>CNS/PNS: ischemic stroke<break></break>Visceral involvement: splenomegaly (100 %).</td></tr><tr><td>H112Q</td><td>3</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: Livedo reticularis, urticarial rash<break></break>CNS/PNS: ischemic and haemorrhagic strokes<break></break>Visceral involvement: hepatomegaly, splenomegaly, portal hypertension<break></break>Immune/hematologic system: Pancytopenia, hypogammaglobulinemia (100 %).</td></tr><tr><td>T119A</td><td>3</td><td>4 in heterozygosis</td><td>Fever (100 %)<break></break>Skin: Livedo reticularis, ulceration of extremities (100 %)<break></break>CNS/PNS: ischemic and haemorrhagic strokes (100 %)</td></tr><tr><td>G142S</td><td>3</td><td>4 in heterozygosis</td><td>Fever (100 %)<break></break>Skin: Livedo reticularis, ulceration of extremities (100 %)<break></break>CNS/PNS: ischemic and haemorrhagic strokes (100 %)</td></tr><tr><td rowspan="2">R169Q</td><td rowspan="2">3</td><td>15 in homozygosis</td><td rowspan="2">Fever (37 %)<break></break>Skin: Livedo reticularis (58 %), skin nodules (4 %), ulcerations at extremities/digital necrosis (8 %), Raynaud’s phenomenon (8 %), purpuric/vasculitic rash (13 %), erythema nodosum (13 %), eczema (20 %)<break></break>CNS/PNS: ischemic stroke (54 %), hemorrhagic stroke (13 %), intracranial haemorrhage (13 %), cranial nerve paralysis (37 %), polineuropathy (8 %), neurosensorial hearing loss (8 %).<break></break>Visceral involvement: abdominal pain (17 %), bowel ulcerations (8 %), chronic gastritis (4 %), bowel stenosis (4 %), colitis (4 %), hepatomegaly (45 %), splenomegaly (58 %), acute liver failure (4 %), hypertension (8 %).<break></break>Immune/hematologic system: hypogammaglobulinemia (62 %), pancytopenia (8 %), leucopoenia (20 %), lymphopenia (13 %), granulocytopenia (4 %), anaemia (25 %), thrombocytopenia (4 %),<break></break>lymphadenopathy (25 %), recurrent infections (29 %).</td></tr><tr><td>9 in heterozygosis</td></tr><tr><td>P193L</td><td>4</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: Livedo reticularis, ulcerations at extremities<break></break>CNS/PNS: ischemic stroke, TIA, intracranial haemorrhage, polineuropathy<break></break>Visceral involvement: bowel stenosis, oral aphtae<break></break>Immune/hematologic system: hypogammaglobulinemia (100 %).</td></tr><tr><td>M243R</td><td>4</td><td>2 in heterozygosis</td><td>Fever (50 %)<break></break>Skin: erythema nodosum (50 %)<break></break>CNS/PNS: intracranial haemorrhage (50 %)<break></break>Visceral involvement: splenomegaly (100 %)<break></break>Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (100 %).</td></tr><tr><td>P251L</td><td>4</td><td>4 in heterozygosis</td><td>Fever (25 %)<break></break>Skin: Livedo reticularis (75 %), vasculitic rash (50 %)<break></break>CNS/PNS: ischemic stroke (75 %), cranial nerve paralysis (100 %), neurosensorial hearing loss (25 %).<break></break>Visceral involvement: hypertension (25 %), epididymitis (25 %)</td></tr><tr><td>W264S</td><td>5</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: Livedo reticularis<break></break>Visceral involvement: hypertension, abdominal and renal aneurysm (100 %).</td></tr><tr><td>R306*</td><td>6</td><td>1 in heterozygosis</td><td>Fever<break></break>Skin: rash<break></break>CNS/PNS: ischemic stroke, hemorrhagic stroke, intracranial haemorrhage (100 %)</td></tr><tr><td>N328K</td><td>7</td><td>2 in heterozygosis</td><td>Fever (50 %)<break></break>Skin: Livedo racemosa (50 %), skin nodules (50 %)<break></break>Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (50 %)</td></tr><tr><td>Y453C</td><td>9</td><td>3 in heterozygosis</td><td>Fever (100 %)<break></break>Skin: Livedo reticularis (100 %), urticarial rash (33 %)<break></break>CNS/PNS: ischemic stroke (100 %), haemorrhagic strokes (33 %)<break></break>Visceral involvement: hepatomegaly (66 %), splenomegaly (100 %), portal hypertension (33 %)<break></break>Immune/hematologic system: Pancytopenia (66 %), hypogammaglobulinemia (66 %).</td></tr></tbody></table></table-wrap></p>
<p>In most patients, a neurological involvement, affecting both the peripheral and central nervous system, has been described.</p>
<p>The severity of the CNS involvement is rather variable. In some patients a transitorily ischemic attack (TIA) has been described (with negative cerebral CT and/or MRI), while others developed an ischemic or hemorrhagic stroke (in few cases a ventricular haemorrhage has also been detected). Typically, the strokes associated to DADA2 are lacunar with a wide range of clinical manifestations ranging from clinically silent episodes in few cases, to severe ones leading to a permanent disability [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p>
<p>The neuropathy ranges from a transient mononeuritis (such as a cranial nerve transient paralysis) to a permanent polyneuropathy; moreover, few patients suffered from optic neuritis. In few cases, persistent neurosensorial hearing loss has also been described [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p>
<p>Most patients have gastrointestinal manifestations: abdominal pain, significant weight loss, chronic gastritis, hepatomegaly, splenomegaly, portal hypertension, bowel perforation or stenosis.</p>
<p>While nephrogenic hypertension is rather common in this condition, in few patients focal glomerulosclerosis and renal amyloidosis have also been described [<xref ref-type="bibr" rid="CR11">11</xref>]. Lung involvement with necrotising pneumonia (lethal) has been reported in one patient [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
<p>The blood tests usually reveal an elevation of acute phase reactants (ERS, CRP), low haemoglobin levels and neutrophilic leukocytosis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]; however in few patients cytopenia (pancytopenia, leucopoenia) has been detected [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Auto-antibody are usually negative.</p>
<p>As stated above, a mild immunodeficiency can be observed; some patients present hypogammaglobulinemia that may affect IgM or all Ig subclasses [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Of note, despite the low immunoglobulins’ levels, only few cases displayed an increased susceptibility to infections, that was rather severe in exceptional cases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p>
<p>MRI is the most useful tool in the diagnosis of cerebral strokes; in fact CT scan as well as conventional angiography may not detect the smaller lacunar strokes and therefore underestimate the entity of involvement of the CNS [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
<p>Some patients underwent an angiographic investigation, that revealed the presence of stenosis and/or aneurysms of abdominal artery, particularly mesenteric, celiac, hepatic and renal arteries; the histological analysis, when done, revealed a necrotizing vasculitis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p>
<p>In patients with symptoms suggestive for organ involvement but without pathologic finding in not-invasive radiologic studies, conventional angiography can be of help revealing aneurism and or stenosis in the middle sizes arteries.</p>
<p>Skin biopsy revealed, in most cases, a non-granulomatous, necrotizing vasculitis of small and medium-sized vessels, with the same histopathologic features of polyarteritis nodosa [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p>
<p>In few cases the histology was less specific showing a leucocytoclastic vasculitis or a panniculitis.</p>
<p>Polyarteritis nodosa (PAN) is, according to the Chapel Hill classification, a “Necrotizing arteritis of medium or small arteries without glomerulonephritis or vasculitis in arterioles, capillaries, or venules, and not associated with antineutrophil cytoplasmic antibodies (ANCAs)” [<xref ref-type="bibr" rid="CR22">22</xref>]. It’s gathered in the medium-sized vessels vasculitis, even if it can affect arteries of any size [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
<p>Being DADA2 a vasculitis with a genetic basis, it has been proposed to group this disease in the vasculitis with a probable cause according to the Chapel Hill classification [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p>
<p>Notably, most of the DADA2 patients not only received the histological diagnosis of PAN but also met the EULAR/PRINTO/PRES diagnostic criteria for childhood polyarteritis nodosa (Table <xref ref-type="table" rid="Tab4">4</xref>) [<xref ref-type="bibr" rid="CR23">23</xref>].<table-wrap id="Tab4"><label>Table 4</label><caption><p>EULAR/PRINTO/PRES classification criteria for childhood Polyarteritis nodosa (PAN) [<xref ref-type="bibr" rid="CR23">23</xref>]</p></caption><table frame="hsides" rules="groups"><tbody><tr><td></td><td>Histopathology or angiographic abnormalities (mandatory) plus one of the five following criteria:</td><td>- Histology: necrotising vasculitis in medium or small-sized arteries.<break></break>- Angiography: aneurysm, stenosis or occlusion of a medium or small sized artery,</td></tr><tr><td rowspan="5">EULAR/PRINTO/PRES classification criteria for childhood Polyarteritis nodosa (c-PAN)</td><td>1. Skin involvement</td><td>Livedo reticularis, skin nodules, superficial ulcers, peripheral tissue necrosis</td></tr><tr><td>2. Myalgia/muscle tenderness</td><td>Muscle pain or tenderness</td></tr><tr><td>3. Hypertension</td><td>Blood pressure &gt; 95th centile</td></tr><tr><td>4. Peripheral neuropathy</td><td>Sensory or motor neuropathy</td></tr><tr><td>5. Renal involvement</td><td>Proteinuria, haematuria, impaired function</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec5">
<title>Unusual phenotypes</title>
<p>Even if most of the patients with DADA2 have a clinical phenotype consistent with a systemic inflammatory vasculopathy, a recent report has enlighten that the disease may be dominated by clinical manifestations suggestive for an immune-disrective condition, such as cytopenia, lymphadenopathy, hepatosplenomegaly and immunodeficiency with severe viral infections [<xref ref-type="bibr" rid="CR7">7</xref>]. The two patients described did not present skin involvement and one of them developed a vascular involvement only after bone-marrow transplantation. Of note, the mutations found in these two patients were the same described in patients with a “typical” inflammatory clinical picture.</p>
<p>Similarly a third patient with a lymphoprolipherative clinical picture, resembling Castleman’s syndrome, has been reported by the same group [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p>A more recent clinical series of 9 DADA2 patients with the homozygous R169Q mutation has enlightened that the presence of cytopenia is a common finding of the disease, together with the common inflammatory manifestations [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
<p>In the two patients carrying homozygous 22q11.1 deletion, encompassing both copies of the IL-17 receptor A (<italic>IL17RA</italic>) and the <italic>CECR1</italic> gene, the clinical phenotype was dominated by muco-cutaneous infections and dermatitis associated to persistent inflammation and, in one patient, vasculitis responding to steroids [<xref ref-type="bibr" rid="CR14">14</xref>]. Livedo reticularis, stroke and other DADA2 clinical manifestations were not described.</p>
<p>Finally two brothers with a clinical picture consistent with the diagnosis of common variable immunodeficiency (CVID) were found to be affected by DADA2 by whole exome-sequencing; of note only one of them displayed clinical sign and symptoms consistent with a vasculopathy [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
</sec>
<sec id="Sec6">
<title>Outcome</title>
<p>Being a disease of recent identification, the clinical outcome has not been well investigated. However, from the clinical data by now available is clear that the spectrum of severity of the disease is wide, ranging from patients with neonatal onset and a severe organ involvement to patients with onset in the adulthood and the presence of only skin manifestations (Tables <xref ref-type="table" rid="Tab2">2</xref> and <xref ref-type="table" rid="Tab3">3</xref>); of note, even between patients carrying the same mutations in <italic>CECR1</italic> gene the clinical picture can be widely different (Tables <xref ref-type="table" rid="Tab2">2</xref> and <xref ref-type="table" rid="Tab3">3</xref>).</p>
<p>The disease turned out to be lethal in seven out of the 65 patients by now described [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]: in three cases the severity of the visceral involvement was lethal [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], two patients died for respiratory complications following intracranial haemorrhage [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], while one patient developed necrotising pneumonia [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]; finally one of the two patients carrying the homozygous deletion on 22.11.1 chromosome died for septic shock.</p>
</sec>
<sec id="Sec7">
<title>Treatment</title>
<p>DADA2 is a newly recognised condition and the number of patients so far described is limited; for this reason the response to treatment is largely anecdotal and still controversial (Table <xref ref-type="table" rid="Tab5">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Treatment administrated and clinical response in the described DADA2 patients (1-14)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Therapy</th><th>Case report (number of treated patients)</th><th>Response to treatment</th></tr></thead><tbody><tr><td rowspan="7">Steroids (orally or i.v.)</td><td>Navon et al. (17)</td><td>In 2 cases complete control of the disease with on demand steroidal therapy. In other patients steroid-dependence.</td></tr><tr><td>Zhou et al. (9)</td><td>Partial control of diseases manifestations with high doses of corticosteroids</td></tr><tr><td>Van Eyck et al. (2)</td><td>Steroid-dependence</td></tr><tr><td>Belot et al. (2)</td><td>Steroid-dependence</td></tr><tr><td>Garg et al. (1)</td><td>Steroid-dependence</td></tr><tr><td>Van Montfrans et al. (6)</td><td>Partial response in 3 patients</td></tr><tr><td>Schepp et al. (1)</td><td>Partial response</td></tr><tr><td rowspan="5">cyclophosphamide (orally or i.v.)</td><td>Navon et al. (9)</td><td>Good response in 2 patients.</td></tr><tr><td>Zhou et al. (7)</td><td>Not specified</td></tr><tr><td>Belot et al. (2)</td><td>Partial response</td></tr><tr><td>Garg et al. (1)</td><td>Poor response</td></tr><tr><td>Batu et al. (4)</td><td>Poor response</td></tr><tr><td rowspan="5">Azathioprine</td><td>Navon et al. (7)</td><td>No patients with complete response</td></tr><tr><td>Van Eyck et al. (2)</td><td>Poor response</td></tr><tr><td>Belot et al. (1)</td><td>Good response in association to methotrexate</td></tr><tr><td>Batu et al. (3)</td><td>Poor response</td></tr><tr><td>Van Montfrans et al. (5)</td><td>Not specified</td></tr><tr><td rowspan="4">Methotrexate</td><td>Navon et al. (3)</td><td>Good response in association with other immunosuppressive and biologics</td></tr><tr><td>Belot et al. (1)</td><td>Good response in association with azathioprine</td></tr><tr><td>Batu et al. (3)</td><td>Poor response</td></tr><tr><td>Schepp et al. (1)</td><td>Partial response</td></tr><tr><td>Cyclosporine</td><td>Van Eyck et al. (1)</td><td>Poor response</td></tr><tr><td>Colchicine</td><td>Batu et al. (5)</td><td>Good response in one patient, none response in 4 patients</td></tr><tr><td rowspan="4">Mycophenolate</td><td>Zhou et al. (2)</td><td>Not specified</td></tr><tr><td>Van Eyck et al. (1)</td><td>Poor response</td></tr><tr><td>Belot et al. (1)</td><td>Partial response in association with cyclophosphamide</td></tr><tr><td>Batu et al. (2)</td><td>Good response in one patient, poor in the other</td></tr><tr><td>Sirolimus</td><td>Van Eyck et al. (2)</td><td>Good response in one patient<break></break>Poor response in one patient</td></tr><tr><td>Tacrolimus</td><td>Van Eyck et al. (2)</td><td>Good response in one patient<break></break>Poor response in one patient</td></tr><tr><td rowspan="5">I.v. immunoglobulins</td><td>Navon et al. (1)</td><td>Not specified</td></tr><tr><td>Zhou et al. (5)</td><td>Not specified</td></tr><tr><td>Van Eyck et al. (2)</td><td>Prophylactic dosage</td></tr><tr><td>Belot et al. (1)</td><td>Prophylactic dosage</td></tr><tr><td>Schepp et al. (2)</td><td>Prophylactic dosage</td></tr><tr><td rowspan="3">Anakinra</td><td>Zhou et al. (5)</td><td>Not specified</td></tr><tr><td>Garg et al. (1)</td><td>Initial partial response than relapse</td></tr><tr><td>Van Montfrans et al. (1)</td><td>Good response</td></tr><tr><td>Canakinumab</td><td>Garg et al. (1)</td><td>Initial partial response than relapse</td></tr><tr><td rowspan="4">Etanercept</td><td>Navon et al. (5)</td><td>Complete response in 5 patients<break></break>Partial response in 1 patient</td></tr><tr><td>Zhou et al. (6)</td><td>Not specified</td></tr><tr><td>van Montfrans et al. (3)</td><td>Partial response in 1 pateint<break></break>Complete response in 2 patients</td></tr><tr><td>Batu et al. (3)</td><td>Partial response in 2 patients, complete in 1</td></tr><tr><td>Adalimumab</td><td>Navon et al. (3)</td><td>Complete response in 2 patients, exacerbation in 1 patient</td></tr><tr><td>Infliximab</td><td>Navon et al. (2)</td><td>Complete response in 1 patient<break></break>Partial response in 1 patient</td></tr><tr><td rowspan="3">Tocilizumab</td><td>Zhou et al. (1)</td><td>Not specified</td></tr><tr><td>Van Eyck et al. (1)</td><td>Complete response</td></tr><tr><td>Batu et al. (1)</td><td>Poor response</td></tr><tr><td rowspan="2">Rituximab</td><td>Zhou et al. (1)</td><td>Poor response</td></tr><tr><td>Belot et al. (1)</td><td>Poor response</td></tr></tbody></table></table-wrap></p>
<p>Being an inflammatory condition, high doses of steroids are usually able to control the clinical manifestations [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. However, due to the severity of the condition, a steroid-dependence is often described. None of the most common immunosuppressive drugs (cyclophosphamide, azathioprine, methotrexate) was effective [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p>
<p>Navon et al. reported ten patients treated with anti-TNF drugs (etanercept, adalimumab, infliximab) with complete response in 8, even after the failure of immunosuppressive therapies [<xref ref-type="bibr" rid="CR2">2</xref>]; good results with anti-TNF agents were also reported in other small series [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. By now, the reason why this drug is effective is still unclear.</p>
<p>According to the report of Zhou et al., neither immunosuppressive nor biologic drugs were able to completely control the disease manifestations in all treated patients; the enzymatic substitutive treatment (fresh frozen plasma or recombinant enzyme) was postulated to be of help. This approach was tempted in two patients reported by Batu et al. with a transient good response in one and a not-satisfactory response in the other [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
<p>A possible role of hematopoietic stem cell transplantation (HSCT) has been postulated to be effective by Zhou et al. and Navon et al., being able to provide ADA2 producing monocytes and therefore to normalize the plasmatic levels of the enzyme [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. This therapeutic strategy, performed in one of the two patients reported by Van Eyck et al. [<xref ref-type="bibr" rid="CR7">7</xref>] and in a patient reported by the NIH group [<xref ref-type="bibr" rid="CR3">3</xref>], was able to normalize the plasmatic levels of ADA2 and to control the disease manifestations [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]; early complications occurred in one of them. More recently two additive patients who displayed a complete response to HSCT have been described [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
<p>Van Eyck et al. conclude that HSCT should be suggested only for those patients with a severe disease, since DADA2 patients present an increased risk of HSCT-related complications due to the persistent inflammation and the compromised endothelial integrity [<xref ref-type="bibr" rid="CR7">7</xref>]. Of note, the other patient described in this paper displayed a complete response to treatment with sirolimus; the authors assume that this drug may be of help in the control of the clinical manifestations related to ADA2-deficiency, being able to reduce the M1 macrophage differentiation and the production of IL-6 [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
</sec>
</sec>
<sec id="Sec8">
<title>Conclusion</title>
<p>In conclusion DADA2 is a genetic condition mainly characterized by an inflammatory vasculopathy resembling polyarteritis nodosa (PAN). From the clinical data so far available, the age at onset, the disease manifestations and severity are widely variable. Further clinical studies are therefore needed in order to better understand the phenotypic viability of this condition and the genotype-phenotype correlation.</p>
<p>In light of the data by now available, we consider the genetic analysis of <italic>CECR1</italic> gene suggested in the following clinical pictures: patients with an inflammatory vasculopathy with early onset in infancy, patients with a diagnosis of PAN or cPAN with early onset and/or severe organ involvement (above all stroke), especially in case of a positive family history or consanguinity/endogamy in the parents. Moreover DADA2 should be ruled out in patients with an immune-disreactive condition without an underlying diagnosis, especially in presence of signs or symptoms of vasculitis.</p>
<p>Finally, a better enlightenment of the pathogenetic mechanisms of the disease is needed; these data will be of help also in the identification of an effective treatment.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
<sec id="FPar1">
<title>Funding</title>
<p>Not applicable.</p>
</sec>
<sec id="FPar2">
<title>Availability of data and material</title>
<p>The datasets supporting the conclusions of this article are included within the article (and its additional files).</p>
</sec>
<sec id="FPar3">
<title>Authors’ contributions</title>
<p>RC carried out the review of the available papers on the disease, performed the revision of the genetic and clinical manifestations and drafted the manuscript. FP and FS reviewed the pathogenetic studies of the disease and draft the pathogenesis chapter of the review. MG conceived of the review, participated in its design and helped to draft the manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec id="FPar4">
<title>Competing interests</title>
<p>Marco Gattorno received speaker’s fees from Sobi and Novartis and grant for the Eurofever project from Sobi and Novartis.</p>
</sec>
<sec id="FPar5">
<title>Consent for publication</title>
<p>The consent to publish the clinical image (Fig. <xref ref-type="fig" rid="Fig3">3</xref>) has been obtained from the patient’s parents.</p>
</sec>
<sec id="FPar6">
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ombrello</surname>
<given-names>AK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early-onset stroke and vasculopathy associated with mutations in ADA2</article-title>
<source/>N Engl J Med
          <year>2014</year>
<volume>370</volume>
<fpage>911</fpage>
<lpage>920</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1307361</pub-id>
<pub-id pub-id-type="pmid">24552284</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navon Elkan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pierce</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Segel</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy</article-title>
<source/>N Engl J Med
          <year>2014</year>
<volume>370</volume>
<fpage>921</fpage>
<lpage>931</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1307362</pub-id>
<pub-id pub-id-type="pmid">24552285</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Montfrans</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zavialov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Mutant ADA2 in vasculopathies</article-title>
<source/>N Engl J Med
          <year>2014</year>
<volume>371</volume>
<issue>5</issue>
<fpage>478</fpage>
<pub-id pub-id-type="doi">10.1056/NEJMc1405506</pub-id>
<pub-id pub-id-type="pmid">25075845</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bras</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guerreiro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Santo</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Mutant ADA2 in vasculopathies</article-title>
<source/>N Engl J Med
          <year>2014</year>
<volume>371</volume>
<issue>5</issue>
<fpage>478</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMc1405506</pub-id>
<pub-id pub-id-type="pmid">25075847</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Eyck</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liston</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wouters</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Mutant ADA2 in vasculopathies</article-title>
<source/>N Engl J Med
          <year>2014</year>
<volume>371</volume>
<issue>5</issue>
<fpage>480</fpage>
<pub-id pub-id-type="pmid">25075848</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kasapcopur</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>J</given-names>
<suffix>2nd</suffix>
</name>
<etal></etal>
</person-group>
<article-title>Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy</article-title>
<source/>Eur J Pediatr
          <year>2014</year>
<volume>173</volume>
<issue>6</issue>
<fpage>827</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1007/s00431-014-2320-8</pub-id>
<pub-id pub-id-type="pmid">24737293</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Eyck</surname>
<given-names>L</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Hershfield</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Pombal</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency</article-title>
<source/>J Allergy Clin Immunol
          <year>2015</year>
<volume>135</volume>
<issue>1</issue>
<fpage>283</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2014.10.010</pub-id>
<pub-id pub-id-type="pmid">25457153</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belot</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wassmer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Twilt</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in CECR1 associated with a neutrophil signature in peripheral blood</article-title>
<source/>Pediatr Rheumatol Online J
          <year>2014</year>
<volume>12</volume>
<fpage>44</fpage>
<pub-id pub-id-type="doi">10.1186/1546-0096-12-44</pub-id>
<pub-id pub-id-type="pmid">25278816</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<mixed-citation publication-type="other">Gonzalez Santiago TM, Zavialov A, Saarela J, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol. 2015;1.</mixed-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westendorp</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Nederkoorn</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Aksentijevich</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Unexplained early-onset lacunar stroke and inflammatory skin lesions: consider ADA2 deficiency</article-title>
<source/>Neurology
          <year>2015</year>
<volume>84</volume>
<issue>20</issue>
<fpage>2092</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000001581</pub-id>
<pub-id pub-id-type="pmid">25888558</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batu</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Karadag</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Taskiran</surname>
<given-names>EZ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations</article-title>
<source/>J Rheumatol
          <year>2015</year>
<volume>42</volume>
<issue>8</issue>
<fpage>1532</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.3899/jrheum.150024</pub-id>
<pub-id pub-id-type="pmid">26233953</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<mixed-citation publication-type="other">Van Montfrans JM, Hartman EA, Braun KP, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016.</mixed-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schepp</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bulashevska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mannhardt-Laakmann</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deficiency of adenosine deaminase 2 causes antibody deficiency</article-title>
<source/>J Clin Immunol
          <year>2016</year>
<volume>36</volume>
<issue>3</issue>
<fpage>179</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1007/s10875-016-0245-x</pub-id>
<pub-id pub-id-type="pmid">26922074</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<mixed-citation publication-type="other">Fellmann F, Angelini F, Wassenberg J, et al. IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol. 2015.</mixed-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannelou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Kastner</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>When less is more: primary immunodeficiency with an autoinflammatory kick</article-title>
<source/>Curr Opin Allergy Clin Immunol
          <year>2014</year>
<volume>14</volume>
<issue>6</issue>
<fpage>491</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="doi">10.1097/ACI.0000000000000117</pub-id>
<pub-id pub-id-type="pmid">25337682</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Adenosine</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Deficiency</surname>
<given-names>D</given-names>
</name>
</person-group>
<source/>Gene reviews
          <year>2006</year>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zavialov</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Engstrom</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity</article-title>
<source/>Biochem J
          <year>2005</year>
<volume>391</volume>
<fpage>51</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20050683</pub-id>
<pub-id pub-id-type="pmid">15926889</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zavialov</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Spillmann</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural basis for the growth factor activity of human adenosine deaminase ADA2</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<fpage>12367</fpage>
<lpage>12377</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.083527</pub-id>
<pub-id pub-id-type="pmid">20147294</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Clinical genetics in 2014: New monogenic diseases span the immunological disease continuum</article-title>
<source/>Nat Rev Rheumatol
          <year>2015</year>
<volume>11</volume>
<issue>2</issue>
<fpage>67</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1038/nrrheum.2014.215</pub-id>
<pub-id pub-id-type="pmid">25536483</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zavialov</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Glaichenhaus</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages</article-title>
<source/>J Leukoc Biol
          <year>2010</year>
<volume>88</volume>
<fpage>279</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.1109764</pub-id>
<pub-id pub-id-type="pmid">20453107</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eltzschig</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Sitkovsky</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Robson</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>Purinergic signaling during inflammation</article-title>
<source/>N Engl J Med
          <year>2012</year>
<volume>367</volume>
<fpage>2322</fpage>
<lpage>2333</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra1205750</pub-id>
<pub-id pub-id-type="pmid">23234515</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jennette</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Falk</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Bacon</surname>
<given-names>PA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>2012 revised international chapel hill consensus conference nomenclature of vasculitides</article-title>
<source/>Arthritis Rheum
          <year>2013</year>
<volume>65</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1002/art.37715</pub-id>
<pub-id pub-id-type="pmid">23045170</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pistorio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iusan</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008. Part II: Final classification criteria</article-title>
<source/>Ann Rheum Dis
          <year>2010</year>
<volume>69</volume>
<fpage>798</fpage>
<lpage>806</lpage>
<pub-id pub-id-type="doi">10.1136/ard.2009.116657</pub-id>
<pub-id pub-id-type="pmid">20413568</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>